

CURRICULUM VITAE

Aparna Komatineni, M.D.

EDUCATION

2007-2011 Resident
Neurology Department
Medical College of Wisconsin

1997-2002 S.V. Medical College
University of Health Sciences
Tirupathi, N.T.R.
M.B.B.S (Bachelor of Medicine and Bachelor of
Surgery)

EMPLOYMENT

2011-Present Neurologist
Colorado Springs Neurological Associates
2312 N. Nevada Ave, Suite 100
Colorado Springs, CO 80907

2011-2014 Stroke Medical Director
Penrose Hospital
2222 N. Nevada Ave
Colorado Springs, CO 80907

January 2005-April 2005 Volunteered and assisted Dr. Edward B. Arenson,
Department of Neuro-oncology
Swedish Medical Center
Denver, CO

October 2004-January 2005 Volunteered at Doctors Care
A non-profit organization helping to serve the needy
Littleton, CO

2002-2003 S.V.R.R. Government Hospital, Tirupathi, India

LICENSURES/BOARD CERTIFICATIONS

September 2013 Colorado (Board Certified)

May 20, 2009 53107-20
Wisconsin
Expiration: 10/31/2011

HONORS AND AWARDS

1. Top Doctor, Colorado Springs Award: 2014, 2015, 2016, 2018, 2019, 2020
2. Stroke Medical Director Penrose St. Francis Hospital / Centura, 2011-2015
3. Wisconsin Neurological Society, Forester Award, 2009
4. 19th Annual MCW Research Day, Poster presentation. Finalist for New Investigator Award. Medical College of Wisconsin Research Day Poster Session, September 16, 2009
5. National Talent Search Scholarship awarded by National Council for Educational Research and Training (NCERT) to only to 1% in the nation, 1994-2002

MEMBERSHIPS IN PROFESSIONAL AND HONARARY SOCIETIES

2019-Present	El Paso Clinical Club
2011-Present	El Paso Medical Society
2011-Present	American Medical Society
2008-Present	SVIN – Society for Vascular and Intervention Neurology
2007-Present	AAN – American Academy of Neurology

PUBLICATIONS

1. **Komatineni A**, Pandya D, Kalia JS, Wolfe T, Zaidat, O.O. – ECASS III VS endovascular Therapy in 3-4.5 hours.
2. **Komatineni A**, Kalia JS, Srivatsal S, Kabbani M, Wolfe T, Hussain S, Zaidat, O.O. (2009) How Common is Vertebral Artery Origin Stenosis In Hospitalized Patients Admitted with Ischemic Stroke? A CT Angiography Study, American Academy of Neurology – 61st Annual Meeting – April 25-May 5, 2009, Seattle, WA.
3. **Komatineni A**, Kalia JS, Hussain S, Wolfe S, Pandya D, Srivatsal, Lynch J, Fitzsimmons BF, Zaidat, O.O. (2008) How Common is Vertebral Artery Origin Stenosis in Hospitalized Patients Admitted with Ischemic Stroke? CT Angiography Study Society of Vascular and Interventional Neurology – 2nd Annual Meeting 2008 – October 23-25, 2008, Miami, FL.
4. Kalia JS, Hussain S, Wolfe T, Pandya D, Srivastal S, **Komatineni A**, Lynch J, Fitzsimmons BF, Zaidat, O.O. (2008) Prevalence of Intracranial arterial stenosis on CT Angiography in Ischemic Stroke Admitted in Last year. Society of Vascular and Interventional Neurology – 2nd Annual Meeting 2008 – October 23-25, 2008, Miami, FL.
5. Hussain S, Fitzsimmons BF, Lynch J, Srivtsal S, **Komatineni A**, Kalia JS, Dhruvil P, Zaidat, O.O. (2008) Long-term Clinical and Angiographic Outcomes with the Wingspan Stent for 50-99% Intracranial Stenosis. Society of Vascular

- and Interventional Neurology – 2nd Annual Meeting 2008 – October 23-25, 2008, Miami, FL.
6. Pandya D, Wolfe T, Hussain S, Kalia JS, **Komatineni A**, Srivatsal S, Lynch J, Fitzsimmons BF, Ziadat, O.O. (2008) Measurement of Antiplatelet Inhibition during Neurointerventional Procedures: The Effect of Anti-thrombotic Duration and Loading Dose. Society of Vascular and Interventional Neurology – 2nd Annual Meeting 2008 – October 23-25, 2008, Miami, FL.
 7. Niu T, Kalia JS, **Komatineni A**, Hong SH, Sinson G, Lynch J, Fitzsimmons BF, Zaidat, O.O. Multimodal Endovascular Therapy of Carotid Cavernous Fistula (CCF) Using Coils, N-BCA, Onyx and Stent Graft. Finalist for New Investigator Award. Medical College of Wisconsin Research Day Poster Session – September 16, 2009 – Milwaukee, WI.

RESEARCH EXPERIENCE

1. Sub-Investigator, NIH CHAMP Study: Childhood and Adolescent Migraine Prevention Study.
2. Principal Investigator, TERI-PRO: A prospective, single-arm, clinical setting study to describe the efficacy, tolerability, and convenience of Teriflunomide (Aubagio) treatment using patient reported outcomes in relapsing-remitting MS.
3. Sub-Investigator, A randomized, placebo controlled, double-blind study to evaluate the efficacy, safety, tolerability and pharmacodynamics of belimumab in subjects with generalized Myasthenia Gravis.
4. Principal Investigator, PASSAGE: Long term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started with fingolimod once daily or treated with another approved disease modifying therapy.
5. Principal Investigator, TRANSITION: A two year observational study to evaluate the safety profile of fingolimod in patients with multiple sclerosis who switch from natalizumab to fingolimod.
6. Principal Investigator, MILESTONE: A study to evaluate the efficacy and safety of two dose strengths of extended release tablets for treatment of stable walking deficits in post-ischemic stroke.
7. Principal Investigator, MILESTONE EXT: An extension study to evaluate the long-term safety, tolerability, and efficacy of two dose strengths of dalfampridine-ER twice daily tablets when administered for at least 12 months to subjects with chronic post-ischemic stroke walking deficits who have completed the controlled, double-blind Study DALF-PS-1016.
8. Principal Investigator, ARISE: A Randomized, double-blind, placebo-controlled, parallel-group, multicentered study followed by an open-label treatment phase to evaluate the effect of AMG334 compared to placebo on the change from baseline in monthly migraine days.
9. Principal Investigator, EXPAND: Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis (Core Part) followed by extended treatment with open-label BAF312 to obtain data on long-term safety, tolerability and efficacy (Extension Part).
10. Principal Investigator, POP: Plegridy (Peginterferon β -1a) Real World Effectiveness and Safety Observational Program.

